Antipsychotic-induced hyperprolactinemia and testosterone levels in boys

Hormone Research in Paediatrics

Volumn 77, Issue 4, 2012, Pages 235-240

  Roke, Yvette ^a   Van Harten, Peter N ^a,b   Buitelaar, Jan K ^d,e   Tenback, Diederik E ^a,c   De Rijke, Yolanda B ^f   Boot, Annemieke M ^g  

^a GGz Central Psychiatric Centre   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adolescents; Antipsychotics; Hyperprolactinemia; Puberty; Testosterone

Indexed keywords

ATOMOXETINE; FOLLITROPIN; INHIBIN B; LUTEINIZING HORMONE; MELATONIN; PIMOZIDE; PROLACTIN; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FOLLITROPIN BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; PARAMETRIC TEST; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PUBERTY; SCHOOL CHILD; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CROSS-SECTIONAL STUDIES; DOPAMINE ANTAGONISTS; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; HYPERPROLACTINEMIA; INHIBINS; LUTEINIZING HORMONE; MALE; PUBERTY; PUBERTY, DELAYED; RECEPTORS, DOPAMINE D2; TESTOSTERONE; TIME FACTORS; YOUNG ADULT;

EID: 84861611452     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000337910     Document Type: Article

References (32)

1. McDougle CJ, Stigler KA, Erickson CA, Posey DJ: Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008; 69:15-20.
2. Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, Stigler KA, Bearss K, Butter E, Swiezy NB, Sukhodolsky DD, Ramadan Y, Pozdol SL, Nikolov R, Lecavalier L, Kohn AE, Koenig K, Hollway JA, Korzekwa P, Gavaletz A, Mulick JA, Hall K L, Dziura J, Ritz L, Trollinger S, Yu S, Vitiello B, Wagner A: Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2009; 48: 1143-1154.
3. Halbreich U, Kinon BJ, Gilmore JA, Kahn LS: Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28: 53-67. (Pubitemid 36015661)
4. Calarge CA, Zimmerman B, Xie D, Kuper-man S, Schlechte JA: A cross-sectional evaluation of the effect of risperidone and selective seroton i ne reupta ke in hibitors on bone mineral density in boys. J Clin Psychiatry 2010; 1: 338-347.
5. Roke Y, Van Harten PN, Boot AM, Buitelaar JK: Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 2009; 19: 403-414.
6. Konarzewska B, Wołczynski S, Szulc A, Galinska B, Popławska R, Waszkiewicz N: Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009; 34: 129-139.
7. Medras M, Trzmiel-Bira A, Józków P, Terpiłowski L, Zagocka E, Sicinska-Werner T: Inhibin B and FSH as markers of Sertoli cell function in impaired spermatogenesis. Endokr y nol Pol 2010; 61: 695-698.
8. Howlett TA, Wass JA: Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy. Clin Endocrinol 1989; 30: 131-140. (Pubitemid 19063217)
9. Molitch ME: Medication-induced hyperpro-lactinemia. Mayo Clin Proc 2005; 80:1050-1057.
10. Verhelst J, Abs R: Hyperprolactinemia: pathophysiology and management. Treat Endocrinol 2003; 2: 23-32. (Pubitemid 37051600)
11. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA: Diagnosis and treatment of hyper-prolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 273-288.
12. Duke PM, Litt IF, Gross RT: Adolescents' self-assessment of sexual maturation. Pediatrics 1980; 66:918-920. (Pubitemid 11213631)
13. Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM: Continuing positive secular growth change in The Netherlands 1955-1997. Pediatr Res 2000; 47:316-323. (Pubitemid 30127036)
14. McKenna T: Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol 2009; 71: 466-469.
15. Emlinger MW, Kühnel W, Ranke MB: Reference ranges for serum concentrations of lu-totropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone binding globuline (SHBG), dehydroepian-drosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and young adults. Clin Chem Lab Med 2002; 40:1151-1160. (Pubitemid 36024451)
16. Andersson AM, Skakkebaek NE: Serum in-hibin B levels during male childhood and puberty. Mol Cell Endocrinol 2001; 30:103-107.
17. Kushnir MM, Blamires T, Rockwood AL, Roberts WL, Yue B, Erdogan E, Bunker AM, Meikle AW: Liquid chromatography-tan-dem mass spectrometry assay for andro-stenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem 2010; 56: 1138-1147.
18. Atkins M, Burgess A, Bot tom le y C, R iccio M: Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatr Bull. 1997: 21; 224-226. (Pubitemid 27225823)
19. Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64:663-667. (Pubitemid 36750143)
20. 2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Ge-nomics 2009; 19: 373-382.
21. Troost PW, Lahuis BE, Hermans MH: Prolactin release in children treated with risper-idone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007; 27:52-57. (Pubitemid 46105764)
22. Croonenberghs J, Grieken van S, Wauters A, West van D, Brouw L, Maes M, Deboutte D: Serum testosterone concentration in male autistic youngsters. Neuroendocrinol Lett 2010; 31:483-488.
23. Tordjman S: Plasma androgens in autism. J Autism Developmental Dis 1995; 25: 295-304.
24. Dunbar FV, Kusumakar: Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 2004; 161:918-920.
25. Knickmeyer RC, Wheelwright S, Hoekstra R, Baron-Cohen S: Age of menarche in females with autism spectrum conditions. Dev Med Child Neurol 2006; 48:1006-1011.
26. Wacharasindhu S, Pri-Ngam P, Kongchonrak T: Self-assessment of sexual maturation in Thai children by Tanner photograph. J Med Assoc Thai 2002; 85:308-319.
27. Leone M, Comtois AS: Validity and reliability of self-assessment of sexual maturity in elite adolescent athletes. J Sports Med Phys Fitness 2007; 47:361-365.
28. Chan NP, Sung RY, Kong AP, Goggins WB, So HK, Nelson EA: Reliability of pubertal self-assessment in Hong Kong Chinese children. J Paediatr Child Health 2008; 44: 353-358. (Pubitemid 351677487)
29. Schall JI, Semeao EJ, Stallings VA, Zemel BS: Self-assessment of sexual maturity status in children with Crohn's disease. J Pediatr 2002; 14 1: 223-229.
30. Stephen MD, Bryant WP, Wilson DP: Self-assessment of sexual maturation in children and adolescents with diabetes mellitus. En-docr Pract 2008; 14:840-845.
31. Blaicher W, Imhof MH, Gruber DM, Schnee-berger C, Sator MO, Huber JC: Focusing on melatonin's interactions. Gynecol Obstet Invest 1999; 48:179-182.
32. Coker F, Taylor D: Antidepressant-induced hyperprolactinaemia. CNS Drug 2010; 24: 563-574.